Fig 1.
A: Overview of Markov model structure; B: Overview of event pathways. QIV, Quadrivalent influenza vaccine; TIV, Trivalent influenza vaccine; ATIV, Adjuvanted influenza vaccine. *acute complications or acute exacerbation of chronic diseases.
Table 1.
Input data for probability, cost, utilities in non-at-risk and at-risk groups.
Table 2.
Input data for vaccine efficacy in non-at-risk and at-risk groups.
Table 3.
Expected clinical outcome of trivalent, quadrivalent, and adjuvanted influenza vaccines.
Table 4.
Base case analysis (per-person costs and effectiveness).
Table 5.
Subgroup analysis based on age and medical conditions (per-person costs and effectiveness).
Fig 2.
(A) Quadrivalent influenza vaccine (QIV) and (B) Adjuvanted trivalent influenza (ATIV) in the elderly aged 65 and above.
Fig 3.
Probabilistic sensitivity analysis.
Quadrivalent influenza vaccine (QIV was favored over 99% for willingness to pay (WTP) USD 35,731/QALY compared to TIV) and adjuvanted trivalent influenza vaccine (ATIV was cost-saving compared to TIV) among the elderly aged 65 and above. Willingness to pay; WTP.
Table 6.
The scenario analysis where the intervention is only offered for 1 year.